Risultati di ricerca
Investing.com - CTi Biopharma (NASDAQ: CTIC) ha riportato nel primo trimestre utili per azione di -0,140 $, 0,04$ sotto le stime degli analisti di -0,097$.
Oltre alla mielofibrosi, il profilo chinasico di pacritinib suggerisce la sua potenziale utilità terapeutica in condizioni come la leucemia mieloide acuta, la sindrome mielodisplastica, la leucemia mielomonocitica cronica, la malattia del trapianto contro l'ospite (GvHD) e la leucemia linfocitica cronica (CLL), grazie alla sua inibizione di JAK2...
30 mag 2022 · Cell-based therapeutics are an emerging modality with the potential to treat many currently intractable diseases through uniquely powerful modes of action.
22 nov 2021 · In this review article, we delineate the vast types of cell therapy, including stem cell-based and non–stem cell-based cell therapies, and create the first-in-literature compilation of the different “multicellular” therapies used in clinical settings.
26 feb 2021 · Cell therapies represent a major frontier and paradigm shift in biotechnology.
- Lily Li‐Wen Wang, Lily Li‐Wen Wang, Lily Li‐Wen Wang, Morgan E. Janes, Morgan E. Janes, Morgan E. Ja...
- 2021
3 apr 2013 · Four killer applications for cell-based therapeutics are shown: immune cells engineered to recognize and kill tumor cells, transplanted microbiota that detect and treat intestinal inflammation (e.g., Crohn’s disease) by producing an anti-inflammatory small molecule or biologic, a combination bacterial/mammalian cell therapeutic in ...
30 mag 2022 · Cell-based therapeutics are an emerging modality with the potential to treat many currently intractable diseases through uniquely powerful modes of action.
